Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302

被引：0
|
作者：
Yosuke Kawashima
Toshiyuki Harada
Yuka Fujita
Taku Nakagawa
Kana Watanabe
Naoto Morikawa
Kei Takamura
Kenya Kanazawa
Tomoya Kuda
Kazuhiro Usui
Akimasa Sekine
Akira Inoue
Shunichi Sugawara
机构：
[1] Sendai Kousei Hospital,Department of Pulmonary Medicine
[2] JCHO Hokkaido Hospital,Department of Respiratory Medicine
[3] National Hospital Organization Asahikawa Medical Center,Department of Respiratory Medicine
[4] Omagari Kosei Medical Center,Department of Thoracic Surgery
[5] Miyagi Cancer Center,Department of Respiratory Medicine
[6] Iwate Medical University School of Medicine,Division of Pulmonary Medicine, Allergy, and Rheumatology
[7] Obihiro Kosei Hospital,Department of Pulmonary Medicine
[8] Fukushima Medical University School of Medicine,Department of Pulmonary Medicine
[9] Naha City Hospital,Department of Respiratory Medicine
[10] NTT Medical Center Tokyo,Division of Respirology
[11] Kanagawa Cardiovascular and Respiratory Center,Department of Respiratory Medicine
[12] Tohoku University School of Medicine,Department of Palliative Medicine
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Carboplatin; Albumin-bound paclitaxel; Cisplatin; Gemcitabine; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：515 / 522
页数：7
相关论文
共 50 条
  • [21] A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)
    Wang, Zhen
    Huang, Cheng
    Yang, Jin-Ji
    Song, Yong
    Cheng, Ying
    Chen, Gong-Yan
    Yan, Hong-Hong
    Ben, Xiao-Song
    Wang, Bin-Chao
    Xu, Chong-Rui
    Jiang, Ben-Yuan
    Zhou, Qing
    Chen, Hua-Jun
    Wu, Yi-Long
    EUROPEAN JOURNAL OF CANCER, 2019, 109 : 183 - 191
  • [22] Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer
    Yuichi Takiguchi
    Shunichiro Iwasawa
    Koichi Minato
    Yosuke Miura
    Akihiko Gemma
    Rintaro Noro
    Kozo Yoshimori
    Masato Shingyoji
    Mitsunori Hino
    Masahiro Ando
    Hiroaki Okamoto
    International Journal of Clinical Oncology, 2015, 20 : 659 - 667
  • [23] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
    Jin, Min
    Liu, Hong-Li
    Xue, Jun
    Ma, Hong
    Liu, Jun-Li
    Lin, Zhen-Yu
    Wang, Jing
    Bao, Le-Qun
    Luo, Zhi-Guo
    Yu, Xiong-Jie
    Li, Shuang
    Hu, Jian-Li
    Zhang, Tao
    ONCOLOGIST, 2024, 29 (10): : e1406 - e1418
  • [24] Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302
    Takashi Kasai
    Kiyoshi Mori
    Tomohide Sugiyama
    Nobuyuki Koyama
    Yoichi Nakamura
    Fumiyoshi Ohyanagi
    Hiroki Fukuda
    Eishin Hoshi
    Kunihiko Kobayashi
    Mitsuo Nakayama
    International Journal of Clinical Oncology, 2022, 27 : 1841 - 1848
  • [25] A study of gemcitabine-cisplatin vs paclitaxel-carboplatin chemotherapy in patients with advanced squamous cell carcinoma of the lung
    Rajan, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S74 - S74
  • [26] Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
    Kamata, Ken
    Imai, Hajime
    Matsumoto, Hisakazu
    Yamashita, Yukitaka
    Kato, Takao
    Nishi, Katsuhisa
    Omoto, Shunsuke
    Minaga, Kosuke
    Yamao, Kentaro
    Hyodo, Tomoko
    Im, Sung-Woon
    Hara, Akane
    Yoshikawa, Tomoe
    Ishikawa, Rei
    Okamoto, Ayana
    Yamazaki, Tomohiro
    Nakai, Atsushi
    Ueshima, Kazuomi
    Chiba, Yasutaka
    Takenaka, Mamoru
    Watanabe, Tomohiro
    Kitano, Masayuki
    Kudo, Masatoshi
    JGH OPEN, 2023, 7 (09): : 659 - 666
  • [27] Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302
    Kasai, Takashi
    Mori, Kiyoshi
    Sugiyama, Tomohide
    Koyama, Nobuyuki
    Nakamura, Yoichi
    Ohyanagi, Fumiyoshi
    Fukuda, Hiroki
    Hoshi, Eishin
    Kobayashi, Kunihiko
    Nakayama, Mitsuo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1841 - 1848
  • [28] A phase II trial of nab-paclitaxel and gemcitabine in patients with non-small cell lung cancer previously treated with platinum based chemotherapy
    Hatakeyama, Y.
    Tachihara, M.
    Kiriu, T.
    Hata, A.
    Nagano, T.
    Yamamoto, M.
    Kobayashi, K.
    Ohnishi, H.
    Katakami, N.
    Nishimura, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S102 - S102
  • [29] Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer
    Lilenbaum, RC
    Chen, CS
    Chidiac, T
    Schwarzenberger, PO
    Thant, M
    Versola, N
    Lane, SR
    ANNALS OF ONCOLOGY, 2005, 16 (01) : 97 - 101
  • [30] Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial
    Liu, Guo-Ying
    Ye, Yan-Fang
    Jiang, Yao-Fei
    Chen, Gina Jinna
    Xia, Wei-Xiong
    Huang, Yi-Sheng
    Gao, Tian-Sheng
    Liu, Yi-Min
    Hou, Ya-Ting
    Li, Jian-Fei
    Liu, Jia-Hao
    Lu, Nian
    Chen, Chang-Long
    Ke, Liang-Ru
    Liang, Hu
    Bei, Wei-Xin
    Li, Wang-Zhong
    Dong, Shu-Hui
    Liu, Qin
    Xie, Changqing
    Yao, He-Rui
    Xiang, Yan-Qun
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 385
12345